temozolomide has been researched along with Cerebral Primitive Neuroectodermal Tumor in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 9.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 5.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ)." | 5.19 | Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. ( Abate, ME; Barone, G; Cefalo, G; Colosimo, C; Garrè, ML; Madon, E; Mascarin, M; Massimino, M; Perilongo, G; Potepan, P; Riccardi, R; Ridola, V; Ruggiero, A; Spreafico, F, 2014) |
| "Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy." | 5.12 | Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007) |
| " The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
| "Angiocentric gliomas have recently been reclassified as a separate central nervous system tumor." | 2.48 | Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature. ( Aguilar, HN; Hung, RW; Kotylak, T; Mehta, V, 2012) |
| "Central nervous system primitive neuroectodermal tumors (CNS PNETs) mostly occur in children and present as cerebellar medulloblastoma." | 1.48 | A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics. ( Chen, Z; Dong, Y; He, X; Tong, D, 2018) |
| "Peripheral primitive neuroectodermal tumors of the lumbar paraspinal region with diffuse and strong glial differentiation have never been reported before." | 1.48 | Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide. ( Botros, J; El Ahmadieh, TY; Gluf, W; Kabangu, JL; Pan, E; Raisanen, JM, 2018) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 1.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "In seven MB/PNET cell lines investigated, MGMT promoter methylation was detected only in D425 human MB cells as assayed by the qualitative methylation-specific PCR and the more quantitative pyrosequencing assay." | 1.37 | Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma. ( Arnold, L; Faoro, D; Gerber, NU; Grotzer, MA; Haybaeck, J; Hegi, M; Hürlimann, ML; Mittelbronn, M; Rutkowski, S; Sciuscio, D; Shalaby, T; von Bueren, AO, 2011) |
| "Primitive neuroectodermal tumors (PNET) originating within the spinal cord are extraordinarily rare." | 1.37 | Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse. ( Anson, J; Gollard, RP; Khoury, J; Mason, J; Rosen, L, 2011) |
| "We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years)." | 1.35 | Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. ( Burger, PC; Cochran, EJ; Gujrati, M; Holland, EC; Huse, JT; Jost, SC; Miller, CR; Perry, A; Qian, J; Raghavan, R; Rosenblum, MK; Scheithauer, BW; Zambrano, SC, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, X | 1 |
| Chen, Z | 1 |
| Dong, Y | 1 |
| Tong, D | 1 |
| El Ahmadieh, TY | 1 |
| Raisanen, JM | 1 |
| Botros, J | 1 |
| Kabangu, JL | 1 |
| Pan, E | 2 |
| Gluf, W | 1 |
| Khwaja, R | 1 |
| Mantilla, E | 1 |
| Fink, K | 1 |
| Cefalo, G | 1 |
| Massimino, M | 1 |
| Ruggiero, A | 1 |
| Barone, G | 1 |
| Ridola, V | 1 |
| Spreafico, F | 1 |
| Potepan, P | 1 |
| Abate, ME | 1 |
| Mascarin, M | 1 |
| Garrè, ML | 1 |
| Perilongo, G | 1 |
| Madon, E | 1 |
| Colosimo, C | 1 |
| Riccardi, R | 1 |
| O'Leary, B | 1 |
| Mandeville, HC | 1 |
| Fersht, N | 1 |
| Solda, F | 1 |
| Mycroft, J | 1 |
| Zacharoulis, S | 1 |
| Vaidya, S | 1 |
| Saran, F | 1 |
| Wang, CH | 1 |
| Hsu, TR | 1 |
| Wong, TT | 1 |
| Chang, KP | 1 |
| Oh, J | 1 |
| Bilbao, JM | 1 |
| Tsao, MN | 1 |
| Fazl, M | 1 |
| Guiot, MC | 1 |
| Del Maestro, RF | 1 |
| Perry, JR | 1 |
| Faoro, D | 1 |
| von Bueren, AO | 1 |
| Shalaby, T | 1 |
| Sciuscio, D | 1 |
| Hürlimann, ML | 1 |
| Arnold, L | 1 |
| Gerber, NU | 1 |
| Haybaeck, J | 1 |
| Mittelbronn, M | 1 |
| Rutkowski, S | 1 |
| Hegi, M | 1 |
| Grotzer, MA | 1 |
| Gollard, RP | 1 |
| Rosen, L | 1 |
| Anson, J | 1 |
| Mason, J | 1 |
| Khoury, J | 1 |
| Aguilar, HN | 1 |
| Hung, RW | 1 |
| Mehta, V | 1 |
| Kotylak, T | 1 |
| Terheggen, F | 1 |
| Troost, D | 1 |
| Majoie, CB | 1 |
| Leenstra, S | 1 |
| Richel, DJ | 1 |
| Nicholson, HS | 1 |
| Kretschmar, CS | 1 |
| Krailo, M | 1 |
| Bernstein, M | 1 |
| Kadota, R | 1 |
| Fort, D | 1 |
| Friedman, H | 1 |
| Harris, MB | 1 |
| Tedeschi-Blok, N | 1 |
| Mazewski, C | 1 |
| Sato, J | 1 |
| Reaman, GH | 1 |
| Perry, A | 1 |
| Miller, CR | 1 |
| Gujrati, M | 1 |
| Scheithauer, BW | 1 |
| Zambrano, SC | 1 |
| Jost, SC | 1 |
| Raghavan, R | 1 |
| Qian, J | 1 |
| Cochran, EJ | 1 |
| Huse, JT | 1 |
| Holland, EC | 1 |
| Burger, PC | 1 |
| Rosenblum, MK | 1 |
| Rao, RD | 1 |
| Robins, HI | 1 |
| Mehta, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
Imaging characteristics of an unusual, high-grade angiocentric glioma: a case report and review of the literature.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Cranial Nerve Diseases; Dacarbazine; Diagnos | 2012 |
2 trials available for temozolomide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Child; Child, Preschool; | 2014 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
11 other studies available for temozolomide and Cerebral Primitive Neuroectodermal Tumor
| Article | Year |
|---|---|
A primitive neuroectodermal tumor in an adult: Case report of a unique location and MRI characteristics.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Ventricles; Chemotherapy, Adjuva | 2018 |
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Longitudin | 2018 |
Adult Primary Peripheral PNET/Ewing's Sarcoma of the Cervical and Thoracic Spine.
Topics: Adult; Aged; Humans; Male; Neck; Neuroectodermal Tumors, Primitive; RNA-Binding Protein EWS; Sarcoma | 2019 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Recurrent PNET with MGMT methylation responds to temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Magnetic Resonance I | 2009 |
Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; C | 2011 |
Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Chemotherapy, Adjuva | 2011 |
Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cyclophosphamide; Daca | 2007 |
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comb | 2009 |
Late recurrence of a primitive neuro-ectodermal tumor.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cerebellar Neopla | 2001 |